MedCI Announces Strategic Alliance With Genta Incorporated (GETA.OB) to Secure Tesetaxel Licensing Partner
1/27/2010 10:17:34 AM
SANTA CLARA, Calif.--(BUSINESS WIRE)--MedCI LLC, a life-science business consulting services company, announced the formation of a new strategic alliance with Genta Incorporated (OTCBB:GETA) to secure licensing partners for Genta’s small molecule oncology compound, tesetaxel. Tesetaxel is the leading oral taxane in clinical development and is a core component of Genta’s investigational drug portfolio. Under the agreement, MedCI will continue and extend current discussions with leading pharmaceutical companies in South Korea that focus on oncology.
comments powered by